Piper Sandler analyst Do Kim raised the firm’s price target on Travere Therapeutics to $46 from $42 and keeps an Overweight rating on the shares. Filspari received an on-time accelerated approval with a label containing similar language as Tarpeyo, the analyst tells investors in a research note. The analyst believes that while the "more restrictive" label/REMS will slow Filspari’s launch, the full Phase 3 data will enable a broader label and loosen REMS requirements.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Wedbush upgrades Travere Therapeutics to Outperform, raises target to $30
- Travere Therapeutics upgraded to Outperform from Neutral at Wedbush
- Travere Therapeutics price target raised to $40 from $36 at H.C. Wainwright
- Travere Therapeutics price target lowered to $31 from $37 at Barclays
- Travere Therapeutics selloff on approval news overdone, says BofA